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Abstract
Objective: More people are living with the consequences of cancer and comorbid-
ity. We describe frequencies of comorbidities in a colorectal cancer cohort and asso-
ciations with health and well‐being outcomes up to 5 years following surgery.
Methods: Prospective cohort study of 872 colorectal cancer patients recruited
2010 to 2012 from 29 UK centres, awaiting curative intent surgery. Questionnaires
administered at baseline (pre‐surgery), 3, 9, 15, 24 months, and annually up to 5 years.
Comorbidities (and whether they limit activities) were self‐reported by participants
from 3 months. The EORTC QLQ‐C30 and QLQ‐CR29 assessed global health/quality
of life (QoL), symptoms, and functioning. Longitudinal analyses investigated associa-
tions between comorbidities and health and well‐being outcomes.
Results: At baseline, the mean age of participants was 68 years, with 60% male and
65% colon cancer. Thirty‐two per cent had 1 and 40% had ≥2 comorbidities. The
most common comorbidities were high blood pressure (43%), arthritis/rheumatism
(32%), and anxiety/depression (18%). Of those with comorbidities, 37% reported at
least 1 that limited their daily activities. Reporting any limiting comorbidities was asso-
ciated with poorer global health/QoL, worse symptoms, and poorer functioning on all
domains over 5‐year follow‐up. Controlling for the most common individual comor-
bidities, depression/anxiety had the greatest deleterious effect on outcomes.
Conclusions: Clinical assessment should prioritise patient‐reported comorbidities and
whether these comorbidities limit daily activities, as important determinants of recovery
of QoL, symptoms, and functioning following colorectal cancer. Targeted interventions
and support services, including multiprofessional management and tailored assessment
and follow‐up, may aid recovery of health and well‐being in these individuals.
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1 | BACKGROUND
Colorectal cancer (CRC) is one of the most common cancers world-
wide, with an estimated incidence of over 1.3 million, and this is
increasing.1 Five‐year survival rates in the UK stand at 57% and 65%
in the United States.2,3 Colorectal cancer is more likely in older adults,
with 60% of survivors aged over 65 years.4
Comorbidity is defined as the presence of distinct medical condi-
tion(s) in addition to the particular index disease, in this case CRC.5
Multiple comorbidity is progressively more common with age; thus,
older CRC survivors generally present with high levels of comorbid-
ity.6 Colorectal cancer survivors also have higher rates of comorbid
disease compared with the general population,7 with around 40% to
50% of CRC patients reported to have ≥2 comorbidities.8,9
Living with comorbidity after CRC diagnosis is now the norm
rather than the exception. Therefore, investigation into how comor-
bidities affect CRC survivors' health and well‐being has become
increasingly important. Cancer survivors often report poorer health
and well‐being compared to healthy populations, and independently,
long‐term chronic conditions negatively influence quality of life
(QoL).10,11
Whilst there is a growing body of literature exploring the effect of
comorbidities in people recovering from CRC, there is significant
variability in study sample sizes,12,13 participant characteristics,14,15
and time points of assessment,9,12 and it is not always possible to
identify CRC‐specific data in cohort studies that include multiple
tumour groups.16 In addition, investigations of the impact of comor-
bidities on QoL, symptoms, and functioning following a CRC diagnosis
are limited by cross‐sectional design,9,17 a narrow range of out-
comes,17,18 and methods used to determine comorbidity status.17,19
Most studies focus on the number of comorbidities,9,20 or comor-
bidity severity using weighted scales, where severity is based on the
predefined mortality risk of individual conditions, such as the Charlson
Comorbidity Index13,19,21 or similar indices.22 Few studies describe
patient‐reported severity, such as limitations on activities caused by
comorbidities. Those that do are either cross‐sectional, limited to
self‐reported depression, do not exclusively examine the impact of
comorbidity limitation on well‐being, or present data from mixed
tumour groups.12,19,23
Few studies have described associations between comorbidities,
and health and well‐being over time. Associations with pain, fatigue,
and mental well‐being up to 1 year following a CRC diagnosis, and
fatigue and QoL over time in longer term survivors, have been
described, yet only in relation to the number of comorbidities.18,24
The role of individual comorbid conditions is largely overlooked
in studies.
Only one longitudinal study has mapped comorbidity prevalence
up to 1 year; however, this study was nonpopulation based and limited
to CRC survivors >65 years.14 Similarly, no studies describe the
demographic, clinical, and treatment characteristics of CRC survivors
with comorbidities. Using results from the ColoREctal Well‐being
(CREW) study,25 a longitudinal cohort study investigating recovery of
health and well‐being in the 5 years following colorectal cancer, this
paper aims to determine the following:
1) The frequency of comorbidities, their limiting effects on daily
activities, and the frequency of individual comorbid conditions
among CRC survivors.
2) The association between comorbidities, and recovery of QoL,
symptom, and functioning outcomes.
3) The demographic and clinical factors that characterise comorbid
CRC survivors.
2 | METHODS
2.1 | Design
The ColoREctal Well‐being (CREW) study is a prospective longitudinal
cohort study of patients with nonmetastatic CRC undergoing curative
intent surgery. Further details are described elsewhere.25
2.2 | Participants
Eligible patients had a diagnosis of Dukes' stage A‐C colorectal cancer,
were being treated with curative intent surgery, aged ≥18 years, and
able to complete questionnaires. Having a prior cancer diagnosis was
an exclusion criterion.
2.3 | Procedure
Participants were recruited from 29 UK hospitals between November
2010 and March 2012. Self‐report questionnaires were completed
before surgery (baseline), and mailed questionnaires were sent at
regular intervals: 3, 9, 15, 24 months, and annually up to 5 years.
Clinical and treatment characteristics were identified from NHS
medical data. Ethical approval was granted by the UK NHS Health
Research Authority NRES Committee South Central—Oxford B (REC
ref: 10/H0605/31).
2.4 | Measures
Full details of the measures used in CREW have been published.25
Measures that pertain to the findings presented in this paper are
summarised below.
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2.4.1 | Socio‐demographic, clinical, and treatment
data
Clinical and treatment data were obtained (with consent) from medical
notes: tumour site, Dukes' stage, nodal involvement, how CRC was
detected, family history of CRC, presence of a stoma, and neoadjuvant
and adjuvant treatment. Neighbourhood deprivation was derived from
postcodes using the index of multiple deprivation.26 Domestic and
employment status were assessed by participant self‐report in
questionnaires.
2.4.2 | Comorbidity data
Patient self‐reported comorbidity status remains an accurate method
for health research against clinical record review.27 Self‐reported
comorbidity data were collected at 3, 15, 24, 36, 48, and 60 months.
The list relating to 12 individual conditions or disease groups was a
study‐specific measure (not formally validated) informed by Ramsey
et al,12 with format informed by the Self‐Administered Comorbidity
Questionnaire.28 The list (Figure 1) asks whether a doctor has ever
told the participant they have the condition, whether the condition
limits typical daily activities, and the severity of such impact (ranked
from 1 to 7 on Likert scale). At 24 months, an additional question
asked whether each condition had been diagnosed before or after
CRC diagnosis.
2.4.3 | QoL, symptoms, and functioning
Quality of life, symptoms, and functioning were assessed using the
validated European Organisation for Research and Treatment of
Cancer QoL (EORTC QLQ) core (C30) questionnaire29 and the CRC
component (CR29),30 from 3 months onwards.
Global health status/QoL scale of the QLQ‐C30 was used to
represent overall QoL (comprises 2 items). Analyses of symptoms
focussed on those most frequently reported in CRC9,13,31: pain,
fatigue (from QLQ‐C30), urinary, and bowel symptoms (from QLQ‐
CR29). Physical, role, cognitive, emotional, and social functioning was
assessed using QLQ‐C30 subscales.
2.5 | Statistical analysis
Subscale scores from the EORTC questionnaires were calculated
according to published guidelines.29 To avoid problems with multiple
testing of a large number of individual symptoms, summary scores
representing urinary symptoms and bowel symptoms were calculated
by taking the mean of QLQ‐CR29 subscales: (a) urinary frequency,
FIGURE 1 Self‐report comorbidity section of CREW questionnaires
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urinary incontinence, and dysuria for urinary symptoms and (b) blood
and mucus in stool, stool frequency, abdominal pain, pain in
buttocks/anal area/rectum, bloating, flatulence, and faecal inconti-
nence for bowel symptoms.
Because of initial analyses indicating the stability in prevalence
and chronicity of comorbidities over follow‐up, statistical analyses
used 3‐month comorbidity data.
In the first part of the analyses, associations between the number
of comorbidities reported at 3 months and baseline socio‐demo-
graphic, clinical, and treatment factors were assessed using the chi‐
square test or chi‐square test for trend, where appropriate. The index
of multiple deprivation was categorised into quintiles.26 Performance
status was not captured.
For the second part, longitudinal analyses were conducted using
generalised estimating equations, based on all available completed
questionnaires up to 60 months. Analyses assessed the associations
between EORTC subscale scores as dependent variables and comor-
bidities reported at 3 months (5 most prevalent comorbid conditions
and the comorbidity status itself categorised as none, nonlimiting, or
limiting) as independent variables at the 5% significance level. Sepa-
rate models were fitted for each EORTC subscale of global health sta-
tus/QoL, symptoms, and functioning.
The first set of multivariable regression models included inde-
pendent variables separately in each model and was adjusted for
time since surgery and those demographic, clinical, or treatment
factors significantly associated with total numbers of comorbidities
in the first analyses.
The second set of multivariable regression models focused on
examining multiple effects of the significant comorbidity predictors.
Independent (comorbidity) variables statistically significant in the first
set of regression models were put together in the second set, again
adjusting for time since surgery and demographic/clinical/treatment
factors identified as significant in initial analyses.
Participants with missing questionnaires were included in analyses
for time points for which they provided data; there was no imputation
of missing questionnaires, or socio‐demographic, clinical, treatment, or
comorbidity data. Missing data on the EORTC measures were dealt
with using published guidelines.29,30
Longitudinal analyses involving individual comorbidities encompassed
the 5 most prevalent individual conditions (small numbers restricted
detailed analysis for less prevalent comorbidities and any associations
of individual conditions that limited daily activities).
In line with published guidance, clinically meaningful differences
were determined by a >10‐point difference in EORTC subscale
scores.32
3 | RESULTS
3.1 | Participants
One thousand three hundred and fifty eligible individuals were identi-
fied. Of those eligible, 78% (n = 1055) agreed to participate, of whom
86% (n = 909) gave full consent to participate and 14% (n = 146) gave
permission for only clinical data to be collected. Thirty‐seven were
found to be ineligible following surgery. Excluding 11 individuals
who withdrew or died between consent and baseline, 861 participants
consented to follow‐up. This sample is representative of eligible
patients treated during the recruitment period. Response rates were
88% at baseline and 69% at 60 months. Comorbidity data were
available for 99% of those responding (n = 659) at 3 months and
87% (n = 324) at 60 months.
Mean age at baseline was 68 years (range 27 to 95 years). The
majority were of white ethnic origin, and 60% were male. Most partic-
ipants were retired (60%), and over 60% were married or living with a
partner. Most participants had colon cancer (65%), 35% rectal
tumours. Over 53% had Dukes' stage B, 20% had stage C1, and 12%
to 14% had stage A or C2 (1% was undetermined), Eighteen per cent
received neoadjuvant treatment and 46% adjuvant chemotherapy or
radiotherapy.
3.2 | Frequency and impact of comorbidities
At 3 months, 28% reported no comorbidities, 32% reported 1, 23%
2, and 17% 3 or more. Of the 72% (n = 476) with comorbidities,
the median number was 2. Of those with comorbidities, 37%
reported at least 1 that limited their daily activities, with 13%
reporting 2 or more limiting comorbidities (Table 1). The proportion
of limiting comorbidities remained consistent over time. Most partic-
ipants (62% at 3 months) reported that their comorbidities limited
daily activities “moderately”, which remained fairly consistent over
follow‐up (Appendix 1).
3.3 | Individual comorbidities
The most common individual comorbidities reported at 3 months were
high blood pressure (43%), arthritis/rheumatism (arthritis) (32%),
depression/anxiety (18%), diabetes/high blood sugar (diabetes)
(16%), and asthma/chronic lung disease (lung disease) (16%). There
was less than a 7% change in the prevalence of all conditions over
follow‐up (Appendix 2).
Results suggest that the majority of comorbid conditions were
diagnosed prior to CRC diagnosis (participants responded to this
question at 24 months). The exceptions to this were stroke/brain
haemorrhage and liver disease/cirrhosis, of which 50% and 80%
(respectively) were diagnosed following CRC diagnosis. Of note is
TABLE 1 Number of comorbidities and number of limiting comor-
bidities for the CREW cohort (reported at 3 months following primary
CRC surgery)
Number of
Comorbidities
3 months
n = 659
Number of
Limiting
Comorbidities
3 months
n = 476
0 183 (27.7%) 0 249 (52.3%)
1 211 (32.0%) 1 115 (24.2%)
2 150 (22.8%) ≥2 62 (13.0%)
≥3 115 (17.4%) Missing data 50 (10.5%)
Presence
of any
comorbidities
476 (72.2%) Presence of
any limiting
comorbidities
177 (37.2%)
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the relatively high percentage (46%) of comorbid depression/anxiety
diagnosed post CRC diagnosis, although numbers were small for anal-
ysis. All other conditions (apart from inflammatory bowel disease)
were diagnosed before CRC diagnosis in >78% of individuals.
Arthritis and heart failure were reported to be the most limiting
conditions. Of participants reporting these conditions, >50% stated it
limited their daily activities. Stroke/brain haemorrhage, myocardial
infarction, and angina were reported as limiting by ≥40% of
respondents with each condition, and >35% of participants with
depression/anxiety and lung disease reported them as limiting. High
blood pressure was the most prevalent, but least limiting condition.
Of participants with diabetes, 14% reported the condition as
limiting (Appendix 2).
3.4 | Demographic and clinical characteristics
Socio‐demographic, clinical, and treatment characteristics of CRC
patients and their associations with comorbidities are presented in
Appendix 3. Ethnicity is not presented as numbers in minority groups
were too small for analysis. Comorbidities were significantly more
common in older, retired, or unemployed respondents. No significant
associations were found between comorbidities and any other socio‐
demographic, clinical, or treatment factors, nor for comorbidities that
limited daily activities.
3.5 | Comorbidities and QoL, symptom, and
functioning outcomes
Because of high correlation between age and employment status, only
age at baseline was included in the multivariable regression analyses.
The first set of longitudinal multivariable regression models
adjusted for age and time since surgery (from baseline to 60 months)
illustrates that the presence of any limiting comorbidities was
significantly associated with poorer global health status/QoL, symp-
tom, and functioning outcomes across all domains (P < .001), including
increased fatigue, pain, urinary, and bowel symptoms and reduced
physical, role, emotional, cognitive, and social functioning (Appendix 4).
Findings illustrated clinically meaningful differences associated with
the presence of limiting comorbidities across all outcomes (except
for urinary and bowel symptoms). In contrast, the presence of
nonlimiting comorbidities was only significantly associated with
increased pain and worse physical functioning (P < .05).
Of the 5 most prevalent individual comorbid conditions reported
at 3 months, arthritis and depression/anxiety were significantly associ-
ated with poorer global health status/QoL, symptom, and functioning
outcomes across all domains (P < .001). Depression/anxiety appeared
to have the greatest association with poorer outcomes, with clinically
meaningful differences across all outcomes (except for urinary and
bowel symptoms). Lung disease was also significantly associated with
poorer outcomes, with the exception of urinary symptoms. Diabetes
and high blood pressure were significantly associated with increased
pain and poorer physical functioning, with diabetes also associated
with worse urinary symptoms (Appendix 4).
Once adjusted for all significant comorbidity predictors, final
multivariable regression models confirmed that the presence of any
limiting comorbidities remained a statistically strong and significant
predictor of all health and well‐being outcomes (P < .001), with the
exception of emotional functioning (Table 2). The biggest and clinically
significant differences were observed for pain, fatigue, physical, role,
social, and cognitive functioning.
The presence of depression/anxiety remained a statistically signif-
icant and strong predictor of poorer outcomes across all domains, with
the exception of urinary symptoms. Clinically meaningful differences
were observed for global health status/QoL, fatigue, and emotional
and social functioning. Arthritis, diabetes, and high blood pressure
did not remain significantly associated with any outcomes. Lung
disease remained statistically significant only in association with
poorer global health status/QoL and physical functioning (P < .05).
For participants reporting both limiting comorbidities and
depression/anxiety, differences in outcome scores were approxi-
mately doubled for domains including fatigue, pain, physical, role,
and social functioning, with highly clinically significant differences in
outcome scores of >20.
4 | DISCUSSION
This is the first paper to describe the stability of comorbidity preva-
lence, individual comorbidities, and patient‐reported limitations of
comorbidities, and demonstrate their significant associations with
poorer QoL, symptoms, and functioning up to 5 years following CRC
diagnosis. We demonstrate that it is not the presence of comorbidities
per se, but the limitations on daily activities imposed by comorbidities,
which has the greatest impact on health and well‐being.
4.1 | Frequency and prevalence of comorbidity
Our results demonstrate that 27% of CRC survivors (37% of those
with comorbidities) report at least 1 comorbidity that limits their daily
activities. Ramsey et al, the only other study to investigate self‐
reported comorbidity limitation, found similar findings, with 32%
reporting currently limiting comorbidities, although their findings
relate to longer term (>5 years) CRC survivors.12 Our results also
add to the growing evidence that 70% to 80% of CRC survivors are
living with at least 1 comorbidity.9,12,18
Anxiety and depression are increasingly recognised as common
following CRC,17 yet CREW adds to only a handful of studies to
include them in its assessment of comorbidity.8,18 Approximately half
of individuals stated that their depression/anxiety was not pre‐
existing, but was diagnosed after CRC. Despite low response rates
for this question (50%), high rates of depression post cancer diagnosis,
particularly in CRC, have been demonstrated elsewhere.33 The stabil-
ity in prevalence of depression/anxiety in the 5‐year follow‐up
reported here suggests that often, diagnoses may occur within
3 months of a CRC diagnosis. Our findings highlight the importance
of screening for mental well‐being and offering appropriate support.
This is emphasised by research detailing how significantly fewer CRC
survivors actively seek help for psychological problems than for
physical concerns.34
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The frequency of hypertension, arthritis, diabetes, and lung
disease is comparable to other studies,7,18 and reflect their prevalence
in the general population.35 Results demonstrating a ≤10% prevalence
of angina, myocardial infarction, and heart failure in the CREW cohort
are at odds with higher prevalence in other CRC studies, and in the
general population.8,34 This likely reflects differences in the criteria
for assessing conditions, for example as collective “heart disease” or
here, as separate conditions.
4.2 | Association of comorbidities with QoL,
functioning, and symptom outcomes
Our data confirm the importance of understanding whether comorbid-
ities are disrupting daily activities, as these can have a greater,
negative impact on health and well‐being during recovery from CRC.
Even after accounting for all significant comorbidity predictors,
patient‐reported limitations of comorbidities prevailed as a strong
and significant predictor across all QoL, functioning, and symptom
outcomes. The only exception to this was emotional functioning,
where the presence of depression/anxiety held prominent signifi-
cance. Astrup et al also described associations between limitations of
comorbidities and reduced QoL and greater symptom experience,
although their study was not limited to CRC.23 The only other study
to describe similar associations with QoL in CRC patients combined
patient‐reported and predefined severity scores, meaning that results
do not solely reflect patient reports of limitation.12 Studies using
clinically derived assessments (predefined weighted scales) of comor-
bidity severity have been inconsistent in demonstrating a link between
greater severity and poorer QoL.19,22 Weighted severity scores were
designed to predict survival outcomes and therefore do not capture
the complexity and impact of living with comorbidities.21 Research
demonstrating associations between performance status of cancer
patients and QoL outcomes supports limitation of daily activities as
an important influencer of health and well‐being.16 Our findings
demonstrate that self‐reported limitations of comorbidities have an
important and much greater influence on health and well‐being
outcomes, compared to comorbidity presence alone. Whilst the
presence and clinically defined severity of comorbidities are important,
future assessment should include appraisal of how much they disrupt
people's lives.
Perhaps unsurprisingly, the strongest effects of having a limiting
comorbidity were seen with pain, physical, and role functioning out-
comes. Identified associations with pain are supported elsewhere.36,37
However, we describe for the first time the persistent association
between limiting comorbidities and symptom outcomes up to 5 years
post CRC, in particular the association between comorbidities and
poorer urinary and bowel symptoms. Similar associations have been
described in rectal cancer,38 but this is a new finding in CRC. These
findings hold significance, as multiple studies report urinary and bowel
symptoms as predominant, persistent, and burdensome following CRC
treatment.9,31
Previous cross‐sectional studies have demonstrated links
between depression/anxiety and poorer QoL, fatigue, pain, physical,
and emotional functioning in CRC survivors.17,19 Our findings support
and expand on this previous literature by demonstrating that
depression/anxiety is the most significant individual predictor of
poorer health and well‐being outcomes (with the exception of urinary
symptoms) in CRC survivors for up to 5 years, even after adjusting for
the presence of any limiting comorbidities and other individual
conditions. Moreover, our findings suggest a double health and well‐
being burden of having both depression/anxiety and any limiting
comorbidities.
Interestingly, significant associations of arthritis, as the most limit-
ing comorbidity, disappeared for all outcomes after the inclusion of
the presence of any limiting comorbidities in the final models, which
likely accounted for the health importance of arthritis. This finding
suggests that arthritis, by its limiting nature, is associated with
prolonged and poor health and well‐being outcomes, supporting its
associations with greater pain and poorer physical functioning seen
elsewhere.8
4.3 | Study limitations
Previous cancer studies have demonstrated that participants are less
likely to have severe comorbidities than nonresponders.22 This should
be taken into consideration when interpreting results, as it is possible
that our findings may underrepresent the true extent and impact of
comorbidities. Assessment of EORTC QLQ‐C30, QLQ‐CR29, and
comorbidities was not included within questionnaires until 3 months
because of burden of data collection close to diagnosis. Participants
were asked whether comorbidities were diagnosed prior to their
CRC diagnosis at 24 months; as such, responses are liable to recall
bias. The list of comorbidities available for self‐report was limited to
12 individual conditions or disease groups and did not encompass all
potential comorbid conditions (for example, obesity). A prior diagnosis
of cancer was an exclusion criterion, meaning that previous cancer
diagnoses could not be included in comorbidity assessment. Falling
response rates over follow‐up mean that apparent trends in comorbidi-
ties over time need to be interpreted with caution. Any apparent decline
in absolute numbers of individuals reporting comorbidities could be
because of more unwell individuals withdrawing from the study.
4.4 | Conclusions and clinical implications
Our findings highlight the importance of identifying patient‐reported
presence and limitations of comorbidities, as important health and
well‐being predictors both during and beyond CRC treatment. The
stability in prevalence and severity of comorbidity suggests that CRC
patients at risk of poorer outcomes up to 5 years following a diagnosis
can be identified early, and appropriate support put in place. As such,
key consideration should be given to optimising comorbidity manage-
ment before CRC treatment, and clinical follow‐up that incorporates
comorbidity assessment, is individualised, and takes place as soon as
possible following a CRC diagnosis.
The International Society of Geriatric Oncology recommends ger-
iatrician involvement in the management of cancer patients with
comorbidities, and treatment decisions that consider comorbidities.39
We propose that targeted interventions and support services, includ-
ing multiprofessional management and tailored assessment and
follow‐up, may aid recovery of health and well‐being.
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The ColoREctal Well‐being (CREW) study highlights the impor-
tance of including conditions such as musculoskeletal and mood disor-
ders, and patient‐reported limitations, in future clinical and research
assessments of comorbidity. The inclusion of self‐reported health sta-
tus in the assessment of comorbid CRC patients is a recommendation
echoed by NICE multimorbidity guidance40 and could help to identify
CRC patients at risk of reduced health and well‐being.
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